Ding Huaiwei - Key Laboratory of Structure-Based Drug Design and Discovery of Ministry of Education, Shenyang Pharmaceutical University

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 56 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Design, synthesis and evaluation of carbamate-bridged amino acid prodrugs of cycloicaritin with improved antitumor activity, aqueous solubility and phase II metabolic stability

Weiping Wang, Jiaqi Fan, Fengxiao Li,Shuo Gan,Jiaming Zhang, Yanfang Wang, Yingchao Li,Wenchao Li, Zhonggui He,Huaiwei Ding,Yongbing Sun, Tianhong Zhang,

European Journal of Medicinal Chemistry (2024): 116646-116646

Cited0Views0WOSBibtex

Integration of MyD88 inhibitor into mesoporous cerium oxide nanozymes-based targeted delivery platform for enhancing treatment of ulcerative colitis

Hongbing Liu,Muse Ji, Yuti Bi,Peifu Xiao,Jiansong Zhao,Jingxin Gou,Tian Yin,Haibing He,Huaiwei Ding,Xing Tang,Yu Zhang

Journal of controlled release : official journal of the Controlled Release Society（2023）

Cited0Views0WOSBibtex

Discovery of Novel Quindoline Alkaloids Derivatives as Dual CDK2/Topo I Inhibitors

Qingchun Zhao,Yaoguang Huang,Wenwu Liu,Shuoqi Huang,Deping Li,Huaiwei Ding,Xiaowen Jiang,Mingyue Liu, Xin Liu,Chengze Zhu,Limeng Wu,Huanhua Chen,

Social Science Research Network (2022)

Cited0Views0Bibtex

DZW-310, a novel phosphoinositide 3-kinase inhibitor, attenuates the angiogenesis and growth of hepatocellular carcinoma cells via PI3K/AKT/mTOR axis

Yuting Wu,Xiangbo Xu,Mingyue Liu,Xiaochun Qin,Qiong Wu,Huaiwei Ding,Qingchun Zhao

Biochemical pharmacology（2022）

Cited3Views0WOSBibtex

Design, synthesis, and biological evaluation of β-carboline 1,3,4-oxadiazole based hybrids as HDAC inhibitors with potential antitumor effects

Caizhi Tian,Shuoqi Huang,Zihua Xu,Wenwu Liu,Deping Li,Mingyue Liu,Chengze Zhu,Limeng Wu,Xiaowen Jiang,Huaiwei Ding,Qingchun Zhao

Bioorganic & medicinal chemistry letters（2022）

Cited11Views0WOSBibtex

Exploration of 4-(1H-indol-3-yl)cyclohex-3-en-1-amine analogues as HDAC inhibitors: Design, synthesis, biological evaluation and modelling studies

Chengze Zhu,Mingyue Liu,Yue Yuan,Huanhua Chen,Limeng Wu, Zizheng Cong,Qingchun Zhao,Huaiwei Ding

Bioorganic & medicinal chemistry letters（2022）

Cited1Views0WOSBibtex

DHW-221, a Dual PI3K/mTOR Inhibitor, Overcomes Multidrug Resistance by Targeting P-Glycoprotein (P-gp/ABCB1) and Akt-Mediated FOXO3a Nuclear Translocation in Non-small Cell Lung Cancer

Mingyue Liu,Chang Xu,Xiaochun Qin,Wenwu Liu,Deping Li,Hui Jia,Xudong Gao,Yuting Wu,Qiong Wu,Xiangbo Xu,Bo Xing,Xiaowen Jiang,

FRONTIERS IN ONCOLOGY（2022）

Cited8Views0WOSBibtex

ZDQ-0620, a Novel Phosphatidylinositol 3-Kinase Inhibitor, Inhibits Colorectal Carcinoma Cell Proliferation and Suppresses Angiogenesis by Attenuating PI3K/AKT/mTOR Pathway

Xiaochun Qin,Mingyue Liu,Chang Xu,Bo Xing,Xiangbo Xu,Yuting Wu,Huaiwei Ding,Qingchun Zhao

FRONTIERS IN ONCOLOGY（2022）

Cited5Views0WOSBibtex

Neuroprotective effects of kukoamine A on 6-OHDA-induced Parkinson's model through apoptosis and iron accumulation inhibition

Xin Li,Xiao-wen Jiang,Hai-xiao Chu,Qing-chun Zhao,Huai-wei Ding, Chao-hong Cai

Chinese Herbal Medicines（2021）

Cited9Views0WOSBibtex

Zwitterion-Driven Shape Program of Prodrug Nanoassemblies with High Stability, High Tumor Accumulation, and High Antitumor Activity

Guanting Li,Bingjun Sun,Shunzhe Zheng,Lu Xu,Wenhui Tao,Dongyang Zhao,Jiang Yu,Shuwen Fu,Xuanbo Zhang,Haotian Zhang,Yinglei Zhai,Cong Luo,

ADVANCED HEALTHCARE MATERIALS（2021）

Cited12Views0WOSBibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn